Abstract:Bronchopulmonary dysplasia (BPD) is the most common respiratory disorder among infants born extremely preterm. The pathogenesis of BPD involves multiple prenatal and postnatal mechanisms affecting the development of a very immature lung. Their combined effects alter the lung’s morphogenesis, disrupt capillary gas exchange in the alveoli, and lead to the pathological and clinical features of BPD. The disorder is ultimately the result of an aberrant repair response to antenatal and postnatal injuries to the developing lungs. Neonatology has made huge advances in dealing with conditions related to prematurity, but efforts to prevent and treat BPD have so far been only partially effective. Seeing that BPD appears to have a role in the early origin of chronic obstructive pulmonary disease, its prevention is pivotal also in long-term respiratory outcome of these patients. There is currently some evidence to support the use of antenatal glucocorticoids, surfactant therapy, protective noninvasive ventilation, targeted saturations, early caffeine treatment, vitamin A, and fluid restriction, but none of the existing strategies have had any significant impact in reducing the burden of BPD. New areas of research are raising novel therapeutic prospects, however. For instance, early topical (intratracheal or nebulized) steroids seem promising: they might help to limit BPD development without the side effects of systemic steroids. Evidence in favor of stem cell therapy has emerged from several preclinical trials, and from a couple of studies in humans. Mesenchymal stromal/stem cells (MSCs) have revealed a reparatory capability, preventing the progression of BPD in animal models. Administering MSC-conditioned media containing extracellular vesicles (EVs) have also demonstrated a preventive action, without the potential risks associated with unwanted engraftment or the adverse effects of administering cells. In this paper, we explore these emerging treatments and take a look at the revolutionary changes in BPD and neonatology on the horizon.

Perspectives On Probiotics And Bronchopulmonary Dysplasia

Gut Microbiota and Bronchopulmonary Dysplasia.

The emerging roles of microbiome and short-chain fatty acids in the pathogenesis of bronchopulmonary dysplasia

Research progress of respiratory microecology and bronchopulmonary dysplasia

Association between probiotics and bronchopulmonary dysplasia in preterm infants

Risk Factors for Bronchopulmonary Dysplasia Infants with Respiratory Score Greater Than Four: a Multi-Center, Prospective, Longitudinal Cohort Study in China

Lactobacillus plantarum L168 improves hyperoxia-induced pulmonary inflammation and hypoalveolarization in a rat model of bronchopulmonary dysplasia

A lactobacilli-based inhaled live biotherapeutic product attenuates pulmonary neutrophilic inflammation

Role of Gut Microbiota in Neonatal Lung Injury: Implications for Bronchopulmonary Dysplasia

Present and Future of Bronchopulmonary Dysplasia

Change of intestinal microbiota in mice model of bronchopulmonary dysplasia

Diagnosis and management of bronchopulmonary dysplasia

Phenotypes of Bronchopulmonary Dysplasia

Role of Myeloperoxidase, Oxidative Stress, and Inflammation in Bronchopulmonary Dysplasia

Effect of antibiotic-induced intestinal dysbacteriosis on bronchopulmonary dysplasia and related mechanisms

Bronchopulmonary Dysplasia: Pathogenesis and Pathophysiology

Bronchoalveolar Lavage Fluid Microbiota Dysbiosis in Infants with Protracted Bacterial Bronchitis

Temporal Dynamics of Oxidative Stress and Inflammation in Bronchopulmonary Dysplasia

Bronchopulmonary dysplasia: A review of pathogenesis and pathophysiology

Bronchopulmonary Dysplasia: 50 Years after the Original Description